pDONR221_SLC4A2
(Plasmid
#132276)
-
PurposeGateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors
-
Depositing Labs
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 132276 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 * |
* Log in to view industry pricing.
Backbone
-
Vector backbonepDONR221
-
Backbone manufacturerThermo Fisher Scientific
- Backbone size w/o insert (bp) 2550
-
Vector typeMammalian Expression
Growth in Bacteria
-
Bacterial Resistance(s)Kanamycin, 50 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)Stbl3
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameSLC4A2
-
Alt nameHKB3, BND3L, NBND3, EPB3L1, AE2
-
SpeciesH. sapiens (human)
-
Insert Size (bp)3723
-
Entrez GeneSLC4A2 (a.k.a. AE2, BND3L, EPB3L1, HKB3, NBND3)
Cloning Information
- Cloning method Gateway Cloning
- 5′ sequencing primer M13-fwd
- 3′ sequencing primer M13-rev (Common Sequencing Primers)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
For more information on the full Resolute plasmid collection, please see www.addgene.org/depositor-collections/re-solute/. Please provide your feedback on this plasmid to the RESOLUTE consortium by filling out their RESOLUTE repository feedback form: https://forms.office.com/Pages/ResponsePage.aspx?id=0e05yklzmkS7rjFGQL4N7z4feCLQvEJAmVcOCM_u885UN1JJRko0Ukg4TVQwNTZLOUxPQVJWT1NHUCQlQCN0PWcu
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pDONR221_SLC4A2 was a gift from RESOLUTE Consortium & Giulio Superti-Furga (Addgene plasmid # 132276 ; http://n2t.net/addgene:132276 ; RRID:Addgene_132276) -
For your References section:
The RESOLUTE consortium: unlocking SLC transporters for drug discovery. Superti-Furga G, Lackner D, Wiedmer T, Ingles-Prieto A, Barbosa B, Girardi E, Goldmann U, Gurtl B, Klavins K, Klimek C, Lindinger S, Lineiro-Retes E, Muller AC, Onstein S, Redinger G, Reil D, Sedlyarov V, Wolf G, Crawford M, Everley R, ... Steppan CM. Nat Rev Drug Discov. 2020 Jul;19(7):429-430. doi: 10.1038/d41573-020-00056-6. 10.1038/d41573-020-00056-6 PubMed 32265506